Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Endocrinology

Treatment Strategy: Medical vs. Surgical

At a Glance

For adrenal rest tumors linked to CAH, treatment usually starts with carefully supervised steroid optimization to lower ACTH and may shrink the tissue. Surgery is generally considered for uncertain masses, severe pain, fertility rescue, or selected ovarian cases.

The treatment of Adrenal Rest Tumors in CAH is a careful balancing act. Because these tumors are benign (non-cancerous) once confirmed, the goal of treatment is not to remove them at all costs, but to manage their size while protecting your overall health and future fertility [1][2].

🚨 MEDICATION SAFETY WARNING
Never stop, start, or change your steroid doses on your own. Changing doses without your endocrinologist’s guidance can cause a life-threatening adrenal crisis. Always follow an individualized sick-day plan, know when emergency injectable hydrocortisone is needed, and seek urgent care for severe vomiting, collapse, severe weakness, or inability to retain your medication.

The First-Line Approach: Medical Optimization

A common approach to manage these tumors is to address the underlying signal that causes them to grow: ACTH. When your CAH is carefully managed, ACTH levels are suppressed, which often leads to the shrinkage of adrenal rest tissue [3][1].

  • Steroid Adjustments: Doctors may adjust the type or timing of your glucocorticoids (like hydrocortisone, prednisone, or dexamethasone). For example, a small dose of dexamethasone at bedtime has been used in some cases to reduce tumor volume and potentially restore sperm production [4][5]. However, this is not appropriate for everyone; long-acting dexamethasone carries a high risk of glucocorticoid excess and must be closely supervised.
  • Mineralocorticoid Support: Ensuring your fludrocortisone dose is optimized is vital for overall CAH management. While fludrocortisone is adjusted primarily based on blood pressure, electrolytes, and renin—not directly to shrink TARTs—good control of salt-wasting contributes to overall endocrine balance [6][7].
  • The Goal of Medical Therapy: Ideally, optimizing your medication allows the tumors to stabilize or shrink without the need for invasive procedures [8].

The Risks of Overtreatment

While it might seem logical to use the highest possible dose of steroids to “melt” the tumors away, this carries serious long-term risks. Doctors must carefully avoid overtreatment—treatment targets should not be pursued by excessively suppressing ACTH or forcing 17-OHP to normal levels at the expense of side effects. Overtreatment can lead to:

  • Metabolic and Heart Health: Excess steroids are linked to weight gain, high blood pressure (hypertension), and insulin resistance [9][10].
  • Growth and Bone Density: In children, high doses can lead to stunted growth [11]. In adults, it can cause osteoporosis (weak, brittle bones) and an increased risk of fractures [9][12].
  • Cushingoid Features: Physical changes like a “moon face” or purple stretch marks on the skin [13].

Why Routine Surgery is Avoided for Typical TART

Once TART is confidently established, avoiding an unnecessary removal of the entire testicle (orchiectomy) is important. Today, we know that for confirmed TART, routine radical surgery is not indicated [1][14].

  • Benign Nature: Because confirmed TARTs do not spread, there is no “cancer-risk” reason to remove them [15].
  • Complexity: Testis-sparing surgery (TSS)—where only the tumor is removed—is technically difficult because TARTs are often located deep within the center of the testicle near vital structures [16][17].
  • Recurrence: Even if a tumor is surgically removed, it can grow back if ACTH levels are not properly controlled through medication [17].

When is Surgery Considered?

While rare for typical cases, surgery may be discussed in specific, high-stakes situations:

For Testicular Adrenal Rest Tumors (TART) and Suspected Masses:

  • Diagnostic Uncertainty: If an intratesticular mass remains indeterminate, atypical, rapidly growing, or if cancer cannot be safely excluded, a radical inguinal orchiectomy can be the appropriate, standard cancer-safety procedure. Percutaneous biopsies are generally avoided for suspicious testicular masses [1].
  • Persistent Pain: If a confirmed TART is causing chronic, severe discomfort [18].
  • Fertility Rescue: In some cases of azoospermia (no sperm in the semen), an experienced urology team may perform a testis-sparing resection combined with a procedure to retrieve sperm for future use [18][16].

For Ovarian Adrenal Rest Tumors (OART):
OART management is not standardized and is based mostly on rare case reports.

  • Persistent Symptoms: If symptoms like no periods or severe hair growth (virilization) continue despite perfect medication use, a multidisciplinary team will evaluate for many causes, including PCOS or CAH imbalance [19].
  • Discovery During Laparoscopy: Very rarely, OARTs are found and removed during a laparoscopy (a minimally invasive “keyhole” surgery) [20][21]. This is a specialized, individualized decision, because ovarian surgery carries risks and can inadvertently reduce ovarian reserve.

Common questions in this guide

Can medication make an adrenal rest tumor smaller?
Often, careful treatment of CAH lowers ACTH, a hormone that can stimulate adrenal rest tissue, and the tumor may stabilize or shrink. Your endocrinologist may adjust glucocorticoids, but the dose and timing must be individualized. Never change or stop steroid medication without medical guidance.
Do confirmed testicular adrenal rest tumors usually need surgery?
Usually not. Once a testicular adrenal rest tumor is confidently identified as benign, doctors generally use medical treatment and monitoring rather than removing the testicle. Surgery may still be discussed for severe persistent pain, fertility rescue, or uncertainty about whether the mass is cancer.
When is removal of the testicle considered for a CAH-related mass?
A radical inguinal orchiectomy may be considered when a testicular mass is atypical, rapidly growing, remains unclear, or cancer cannot be safely excluded. This is different from routine surgery for a confirmed typical TART, which is benign. A specialist team should review the diagnosis and fertility implications.
Can adrenal rest tumor treatment help with fertility?
Lowering ACTH through well-supervised CAH treatment may reduce tumor size and can sometimes improve sperm production. For azoospermia, an experienced reproductive urology team may consider testis-sparing surgery together with sperm retrieval for future use. Results vary, so fertility goals should be discussed before treatment.
What can happen if steroid doses are increased too much?
Excess glucocorticoids can cause weight gain, high blood pressure, insulin resistance, and Cushing-like changes such as a rounder face or purple stretch marks. In children, high doses may slow growth; in adults, they can weaken bones and raise fracture risk. Treatment goals should be balanced with side effects by an endocrinologist.
What is the sick-day plan for CAH and adrenal rest tumors?
Follow the individualized sick-day instructions from your endocrinologist and know when emergency injectable hydrocortisone is needed. Seek urgent care for severe vomiting, collapse, severe weakness, or inability to keep medication down. Never stop or change steroid doses on your own.
How are ovarian adrenal rest tumors treated?
There is no standardized treatment for ovarian adrenal rest tumors because they are rare. Persistent absent periods or virilization despite appropriate medication should prompt a multidisciplinary evaluation for causes such as CAH imbalance or PCOS. In selected cases, laparoscopy may be considered, but ovarian surgery can reduce ovarian reserve.

Get notified when new evidence is published on adrenal rest tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (21)
  1. 1

    Testicular adrenal rest tumors - Epidemiology, diagnosis and treatment.

    Eyer de Jesus L, Paz de Oliveira AP, Porto LC, Dekermacher S

    Journal of pediatric urology 2024; (20(1)):77-87 doi:10.1016/j.jpurol.2023.10.005.

    PMID: 37845103
  2. 2

    Experience in optimizing fertility outcomes in men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency.

    King TF, Lee MC, Williamson EE, Conway GS

    Clinical endocrinology 2016; (84(6)):830-6 doi:10.1111/cen.13001.

    PMID: 26666213
  3. 3

    Testicular Adrenal Rest Tumors: Current Insights on Prevalence, Characteristics, Origin, and Treatment.

    Engels M, Span PN, van Herwaarden AE, et al.

    Endocrine reviews 2019; (40(4)):973-987 doi:10.1210/er.2018-00258.

    PMID: 30882882
  4. 4

    Individualizing Management of Infertility in Classic Congenital Adrenal Hyperplasia and Testicular Adrenal Rest Tumors.

    Jha S, El-Maouche D, Marko J, et al.

    Journal of the Endocrine Society 2019; (3(12)):2290-2294 doi:10.1210/js.2019-00227.

    PMID: 31745525
  5. 5

    Restoration of reproductive capacity in a male patient with congenital adrenal hyperplasia and bilateral testicular adrenal rest tumors (TARTs) after six months of glucocorticoid intensification: A case report.

    Ahmad J, Ahmad A, Hadid L

    Medicine 2023; (102(49)):e36061 doi:10.1097/MD.0000000000036061.

    PMID: 38065885
  6. 6

    Testicular Adrenal Rest Tumors in Boys and Young Adults with Congenital Adrenal Hyperplasia.

    Kim MS, Goodarzian F, Keenan MF, et al.

    The Journal of urology 2017; (197(3 Pt 2)):931-936 doi:10.1016/j.juro.2016.09.072.

    PMID: 27840017
  7. 7

    Determining clinical and biological indicators for health outcomes in adult patients with childhood onset of congenital adrenal hyperplasia.

    Bachelot A, Golmard JL, Dulon J, et al.

    European journal of endocrinology 2015; (173(2)):175-84 doi:10.1530/EJE-14-0978.

    PMID: 25947139
  8. 8

    Testicular Adrenal Rest Tumour (TART) or Testicular Malignancy: A Clinical Dilemma.

    Roy M, Roy AK, Chatterjee T, Bansal S

    European journal of case reports in internal medicine 2020; (7(8)):001669 doi:10.12890/2020_001669.

    PMID: 32789136
  9. 9

    Challenges in Adolescent and Adult Males With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

    Claahsen-van der Grinten HL, Adriaansen BPH, Falhammar H

    The Journal of clinical endocrinology and metabolism 2025; (110(Supplement_1)):S25-S36 doi:10.1210/clinem/dgae718.

    PMID: 39836620
  10. 10

    Cardiovascular health, growth and gonadal function in children and adolescents with congenital adrenal hyperplasia.

    Mooij CF, Webb EA, Claahsen van der Grinten HL, Krone N

    Archives of disease in childhood 2017; (102(6)):578-584 doi:10.1136/archdischild-2016-311910.

    PMID: 27974295
  11. 11

    Genetics and Pathophysiology of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

    Yang M, White PC

    The Journal of clinical endocrinology and metabolism 2025; (110(Supplement_1)):S1-S12 doi:10.1210/clinem/dgae535.

    PMID: 39836621
  12. 12

    Glucocorticoid Regimens in the Treatment of Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis.

    Whittle E, Falhammar H

    Journal of the Endocrine Society 2019; (3(6)):1227-1245 doi:10.1210/js.2019-00136.

    PMID: 31187081
  13. 13

    Testicular Adrenal Rest Tumor in Two Brothers with a Novel Mutation in the 3-Beta-Hydroxysteroid Dehydrogenase-2 Gene.

    Güven A, Polat S

    Journal of clinical research in pediatric endocrinology 2017; (9(1)):85-90 doi:10.4274/jcrpe.3306.

    PMID: 27476613
  14. 14

    Acute adrenal crisis after orchiectomy for testicular adrenal rest tumors in untreated congenital adrenal hyperplasia.

    de Sousa AGP, Bezerra AA, Chaves CEP

    JCEM case reports 2026; (4(9)):luag224 doi:10.1210/jcemcr/luag224.

    PMID: 42591732
  15. 15

    Prepubertal Screening for Testicular Adrenal Rest Tumors in Boys with Classic Congenital Adrenal Hyperplasia: Emerging Evidence and Practical Implications.

    Ranieri A, Ferrari V, Ortolano R, et al.

    Children (Basel, Switzerland) 2026; (13(8)) doi:10.3390/children13081003.

    PMID: 42650343
  16. 16

    Case series of testicular adrenal rest tumours in boys with congenital adrenal hyperplasia: A single centre experience.

    Karen Leong SW, Wu LL

    The Medical journal of Malaysia 2019; (74(1)):92-93.

    PMID: 30846672
  17. 17

    Testicular tumors of adrenogenital syndrome: From physiopathology to therapy.

    Naouar S, Braiek S, El Kamel R

    Presse medicale (Paris, France : 1983) 2017; (46(6 Pt 1)):572-578 doi:10.1016/j.lpm.2017.05.006.

    PMID: 28549629
  18. 18

    Sperm retrieval and concomitant tumor resection in azoospermic men with congenital adrenal hyperplasia and bilateral testicular adrenal rest tumors: a case report.

    Kavoussi PK, Summers-Colquitt RB, Odenwald KC, et al.

    Journal of assisted reproduction and genetics 2016; (33(4)):545-8 doi:10.1007/s10815-016-0665-9.

    PMID: 26861965
  19. 19

    [Characterization of ovarian adrenal rest tumors in children and adolescent females with congenital adrenal hyperplasia due to 21-hydroxylase deficiency].

    Su Z, Li YY, Ma HM, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2016; (54(6)):414-8 doi:10.3760/cma.j.issn.0578-1310.2016.06.005.

    PMID: 27256226
  20. 20

    Incidental Finding of Bilateral Ovarian Adrenal Rest Tumor in a Patient With Congenital Adrenal Hyperplasia: A Case Report and Brief Review.

    Bouzidi L, Triki M, Charfi S, et al.

    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2021; (24(2)):137-141 doi:10.1177/1093526620980614.

    PMID: 33433255
  21. 21

    A spontaneous pregnancy and live birth in a woman with primary infertility following the excision of an ovarian adrenal rest tumor: A rare case.

    Uyanıkoglu H, Ozer G, Kahraman S

    Clinical and experimental reproductive medicine 2020; (47(4)):319-322 doi:10.5653/cerm.2020.03692.

    PMID: 33105528

This page is for informational purposes only and does not constitute medical advice. Do not change steroid doses yourself; your endocrinologist and urology team should guide treatment, fertility decisions, and your sick-day plan.

Guide contents adrenal rest tumor
Research & Literature
02 Symptoms and Diagnostic Imaging 04 Fertility Preservation & Family Planning